Every 10-Q that Humana Inc. (HUM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HUM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUM filings page.
Humana Inc. reported third‑quarter results and updates in its September 30, 2025 Form 10‑Q. Total revenues were $32.649 billion, up from $29.397 billion a year ago, as premiums rose to $30.711 billion. Net income was $194 million versus $480 million, reflecting a $63 million loss on a business sale and Value Creation charges of $267 million recorded in operating costs. Diluted EPS was $1.62.
For the nine months, revenues reached $97.149 billion (from $88.548 billion) and net income was $1.979 billion (from $1.897 billion). The effective tax rate for the quarter was (77.3)%, driven by a tax loss on sale of business realizable via capital loss carryback.
Liquidity strengthened: cash and cash equivalents were $5.388 billion (from $2.221 billion at year‑end). Humana issued $1.481 billion of senior notes in March 2025, repaid $577 million notes at maturity, and ended with long‑term debt of $12.607 billion. Shareholder returns included $0.885 per‑share quarterly dividends and $100 million of repurchases year‑to‑date; remaining repurchase authorization was $2.8 billion as of November 4, 2025. Medicare Part D changes effective January 1, 2025 capped beneficiary out‑of‑pocket costs at $2,000.
Humana Inc. (NYSE: HUM) filed its Q2-25 Form 10-Q. Premium and service revenues rose 10% YoY to $32.4 bn for the quarter and 9% YoY to $64.5 bn for the first half. Growth was driven by Medicare Advantage membership and higher services revenue.
Quarterly results weakened: operating income fell 4% to $1.1 bn, while net income dropped 20% to $545 m ($4.51 diluted EPS vs. $5.62). Benefit expense grew 10% and other expense jumped to $200 m, reflecting value-creation and impairment charges. The medical benefit ratio ticked up 90 bp to 89.8%.
Year-to-date performance stronger: YTD net income climbed 26% to $1.79 bn with diluted EPS of $14.81 (+26%), aided by lower benefit ratio (88.4%) and higher operating margins.
Balance sheet: cash & equivalents doubled to $4.0 bn; total assets $50.4 bn. Long-term debt rose to $12.6 bn after issuing $1.5 bn of new senior notes (5.55% 2035; 6.00% 2055) and retiring $600 m notes due 2025. A new $5 bn 5-year revolving credit facility replaced prior lines; no outstanding borrowings.
Capital return: $100 m share buybacks (0.4 m shares at $234 avg) and $0.885 quarterly dividend ($321 m YTD). Remaining authorization: $2.8 bn.
Key risks & items: Medicare Part D redesign effective 2025, ongoing cost-saving initiatives (additional charges expected), $32 m intangible impairment, and put/call obligations on WCAS clinic JV valued at $1.25 bn. Effective tax rate 24.6%. Shares outstanding 120.3 m.